Stock RNA AVIDITY BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
23.04 USD -2.17% Intraday chart for Avidity Biosciences, Inc. -9.11% +154.59%
Apr. 04 Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing MT
Apr. 04 Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing
MT
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing
MT
Avidity Biosciences to Participate in Upcoming Investor Conferences
PR
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Avidity Biosciences, Inc. announced that it has received $400.208766 million in funding
CI
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing
MT
Cantor Fitzgerald Starts Avidity Biosciences With Overweight Rating, $60 Price Target
MT
Transcript : Avidity Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:05 PM
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing
MT
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing
MT
Chardan Ups Price Target on Avidity Biosciences to $33 From $23 on Efficacy, Safety DM1 Data, Keeps Buy Rating
MT
Transcript : Avidity Biosciences, Inc. - Shareholder/Analyst Call
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
PR
Avidity Biosciences Announces Positive Aoc 1001 Long-Term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 Harbor? Trial
CI
North American Morning Briefing : Stock Futures -2-
DJ
Avidity Biosciences Honors Rare Disease Day
AQ
Avidity Biosciences Honors Rare Disease Day®
PR
Apprehension About Key Inflation Data Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday
MT
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
PR
Avidity Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNA Stock
  4. News Avidity Biosciences, Inc.